CureDuchenne » Treatment

Dystrophins, Utrophins, and Associated Scaffolding Complexes: Role in Mammalian Brain and Implications for Therapeutic Strategies

CureDuchenne — Mon, 02 Aug 2010 18:59:36 +0000

Please take some time to read this article and how it relates to the possible treatment of Duchenne muscular dystrophy.

Dystrophins, Utrophins, and Associated Scaffolding Complexes: Role in Mammalian Brain and Implications for Therapeutic Strategies

Less is More: Therapeutic Exon Skipping for Duchenne Muscular Dystrophy Please take some time to read this important report: Therapeutic...
Prosensa’s RNA Based Therapeutic PRO051 Shows Favourable Results in the First Systemic Study in Patients with Duchenne Muscular Dystrophy Please take some time to read this exciting Press Release...
Dr. Barry Byrne, one of Cure Duchenne’s scientific advisors, talks about his role in the movie, “Extraordinary Measures” CureDuchenne is very honored to have Dr. Barry Byrne as...

Related posts brought to you by Yet Another Related Posts Plugin.

TREAT-NMD Presents Annemieke Aartsma-Rus’s Overview of DMD Research

CureDuchenne — Fri, 15 Jan 2010 17:41:00 +0000

Please take some to head over to an important article on Treat-NMD’s website to learn about Annemieke Aartsma-Rus’s overview of Duchenne muscular dystrophy (DMD) research:

TREAT-NMD presents Annemieke Aartsma-Rus’s overview of DMD research

AVI BioPharma Presents Safety Data in Duchenne Muscular Dystrophy at 14th Annual International Congress of the World Muscle Society Please take some time to read this important report: AVI...
TREAT-NMD, EMEA, & Patient Group Workshop on Antisense Oligonucleotide Therapies in Duchenne Muscular Dystrophy Please take some time to read this important Press Release:...
Exciting Research Portfolio CureDuchenne’s mission is our name…to cure Duchenne muscular dystrophy. Our...

Related posts brought to you by Yet Another Related Posts Plugin.

A Note from Cure Duchenne Founder, Debra Miller

CureDuchenne — Tue, 12 Jan 2010 01:15:41 +0000

Today BioMarin announced they will initiate a human trial for a drug that will hopefully up-regulate Utrophin. This is very exciting news since we have hope that Utrophin could be an adequate substitute for dystrophin, the protein that is lacking in patients with Duchenne muscular dystrophy (DMD). This is the very first Utrophin drug to make it to human clinical trials – We applaud Dr. Kay Davies for developing this drug, to BioMarin for investing in this drug, and for Action Duchenne for helping fund it along the way.

My hope is that next year at this time, we will have several new drugs in the trial process for DMD and that the ones already in trial, prove to be effective and safe. The funding for the early development of these drugs is crucial and I’d like to encourage anyone who has an interest in curing DMD to become active in raising funds for research.

Of course, we’d love to have you join us in the many fundraising opportunities that CureDuchenne provides, such as our upcoming mountain climb and bike relay. These will be announced shortly.

Debra Miller

BioMarin Initiates Phase 1 Clinical Study of BMN 195 for Duchenne Muscular Dystrophy Please take some time to read this important press release...
Almost Half a Million Raised at Cure Duchenne Gala Cure Duchenne Founders, Paul and Debra Miller, were recently featured...
Prosensa and GlaxoSmithKline Form Alliance to Fight Duchenne Muscular Dystrophy CureDuchenne is very pleased to forward this announcement from Prosensa. ...

Related posts brought to you by Yet Another Related Posts Plugin.